MorphoSys AG (MOR) Given Average Rating of “Hold” by Brokerages

Share on StockTwits

MorphoSys AG (ETR:MOR) has been assigned a consensus rating of “Hold” from the ten ratings firms that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is €101.30 ($117.79).

MOR has been the topic of several research analyst reports. Goldman Sachs Group set a €114.00 ($132.56) price target on shares of MorphoSys and gave the company a “neutral” rating in a research note on Friday, January 18th. JPMorgan Chase & Co. set a €135.00 ($156.98) price target on shares of MorphoSys and gave the company a “buy” rating in a research note on Monday, January 28th. Oddo Bhf set a €116.00 ($134.88) price target on shares of MorphoSys and gave the company a “buy” rating in a research note on Monday, November 19th. Royal Bank of Canada set a €65.00 ($75.58) price target on shares of MorphoSys and gave the company a “sell” rating in a research note on Monday, February 4th. Finally, Deutsche Bank set a €130.00 ($151.16) price target on shares of MorphoSys and gave the company a “buy” rating in a research note on Monday, December 10th.

MorphoSys stock traded up €0.20 ($0.23) during trading hours on Friday, hitting €87.05 ($101.22). 271,804 shares of the stock were exchanged, compared to its average volume of 153,687. The company has a current ratio of 11.51, a quick ratio of 11.21 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $2.74 billion and a price-to-earnings ratio of -97.26. MorphoSys has a 12 month low of €76.45 ($88.90) and a 12 month high of €124.90 ($145.23).

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Recommended Story: Purposes and Functions of the Federal Reserve

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.